Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: JimmyD who wrote (957)	12/30/1998 2:54:00 AM
From: Miljenko Zuanic	Respond to of 1477

FIBLAST = recombinant basic fibroblast growth factor or FGF-2 Thanks for note. Miljenko

To: JimmyD who wrote (957)	12/30/1998 8:56:00 AM
From: ubrx	Read Replies (1) \| Respond to of 1477

Jimmy D & Miljenko, I asked Scios Investor Relations about that German study several months ago. The Fibroblast used in the study was not Scios' Fiblast but rather a very similar growth factor. I believe they said it was an acidic rather than a basic fibroblast growth factor. There are certainly several different angiogenic growth factors in research. Scios is a player in this field with two major entries, bFGF and VEGF121, but is seems that others are further advanced with the research at this point. Miljenko, do you know of any internet sites that would give good background information on all the angiogenic growth factors in research? Jim P.S. Do you think Fiblast is valued at all in the stock price of SCIO? It seems to me that based on Natrecor's potential alone SCIO is worth more than the current price. Comments?